Therapeutic Potential of Oral Tofacitinib in Alopecia Areata: A Retrospective Study
October 2024
in “
International Journal of Research in Dermatology
”
TLDR Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
This retrospective study evaluated the long-term efficacy and safety of oral tofacitinib in 69 patients with various forms of alopecia areata (AA) from January 2017 to October 2022. The results showed that 46.5% of patients had a very good response, and 4.3% had an excellent response, with 44.9% experiencing no recurrence. Minimal adverse effects were reported, such as acneiform eruptions and upper respiratory tract infections. The study concluded that tofacitinib is a promising treatment for moderate to severe AA, with no serious side effects observed, making it a potential primary treatment option.